Immunic

Yahoo Finance • 13 days ago

Immunic regains compliance with Nasdaq minimum bid price requirement

* Immunic (IMUX [https://seekingalpha.com/symbol/IMUX]) on Wednesday said it has received written notice from Nasdaq, informing that it has regained compliance with the minimum bid price requirement as the closing bid price of the compan... Full story

Yahoo Finance • 13 days ago

Immunic Regains Compliance with Nasdaq Minimum Bid Price Requirement

NEW YORK, April 1, 2026 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases, today announced that it received written notice (the "Noti... Full story

Yahoo Finance • 14 days ago

Immunic appoints biopharmaceutical executive Jon Congleton to board

Immunic appoints biopharmaceutical executive Jon Congleton to board Proactive uses images sourced from Shutterstock Immunic Inc (NASDAQ:IMUX, FRA:10VA) has announced the appointment of veteran biopharmaceutical executive Jon Congleton to... Full story

Yahoo Finance • last month

Immunic secures $400M to support late-stage MS trials - ICYMI

Immunic secures $400M to support late-stage MS trials - ICYMI Proactive uses images sourced from Shutterstock Immunic Inc (NASDAQ:IMUX) earlier this week outlined how a newly secured up to $400 million private placement is set to support... Full story

Yahoo Finance • 2 months ago

Immunic Announces Oversubscribed Private Placement of up to USD 400 Million to Accelerate Transformation into Commercial-Stage Company

– Upfront Proceeds of USD 200 Million, with Potential for up to USD 200 Million in Additional Proceeds – – Expected to Fund Completion of Phase 3 ENSURE Trials in Relapsing Multiple Sclerosis, Initiation of Phase 3 Trial in Primary Progre... Full story

Yahoo Finance • 5 months ago

Immunic GAAP EPS of -$0.13 beats by $0.06

* Immunic press release [https://seekingalpha.com/pr/20305667-immunic-inc-reports-third-quarter-2025-financial-results-and-provides-corporate-update] (IMUX [https://seekingalpha.com/symbol/IMUX]): Q3 GAAP EPS of -$0.13 beats by $0.06.... Full story

Yahoo Finance • 5 months ago

Datadog, Trade Desk upgraded: Wall Street's top analyst calls

The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The Fly. Top Upgrades: KeyBanc upgraded Datadog (DDOG) to Overw... Full story

Yahoo Finance • 6 months ago

ROTH to Host 4th Annual Healthcare Opportunities Conference on October 9 in New York City

NEW YORK, Oct. 01, 2025 (GLOBE NEWSWIRE) -- via IBN -- ROTH Capital Partners, LLC (“ROTH”), www.roth.com, is pleased to announce it will host the 4th Annual ROTH Healthcare Opportunities Conference on October 9, 2025, at the Metropolitan... Full story

Yahoo Finance • 9 months ago

Immunic board authorizes up to 35 million stock appreciation rights for employees

Immunic, Inc. (NASDAQ:IMUX), a clinical-stage biopharmaceutical company with a market capitalization of approximately $80 million, announced that on Monday its board of directors authorized grants of up to 35,000,000 stock appreciation rig... Full story

Yahoo Finance • 10 months ago

Immunic reports low disability worsening rates in MS drug trial

NEW YORK - Immunic, Inc. (NASDAQ:IMUX) announced Tuesday that 92.3% of patients treated with its experimental multiple sclerosis drug vidofludimus calcium remained free of 12-week confirmed disability worsening after 144 weeks of treatment... Full story

Yahoo Finance • 3 years ago

After Positive Data In Ulcerative Colitis Study, Immunic Prioritizes Vidofludimus Calcium Program With One More Candidate

Immunic, Inc (NASDAQ: IMUX) reported data from the maintenance phase of its phase 2b CALDOSE-1 trial of lead asset, vidofludimus calcium (IMU-838), in patients with moderate-to-severe ulcerative colitis (UC). Data showed a dose-linear incr... Full story

Yahoo Finance • 3 years ago

Immunic, Inc. (NASDAQ:IMUX) Q4 2022 Earnings Call Transcript

Immunic, Inc. (NASDAQ:IMUX) Q4 2022 Earnings Call Transcript February 23, 2023 Jessica Breu: Good morning and welcome to Immunic's Fourth Quarter and Year End 2022 Earnings Call. My name is Jessica Breu, Head of Investor Relations and Com... Full story

Yahoo Finance • 3 years ago

Immunic, Inc. Reports Year End 2022 Financial Results and Provides Corporate Update

– Initial Results From Ongoing Part C of Phase 1 Clinical Trial of IMU-856 in Celiac Disease Expected Mid-2023 – – Interim Results From Phase 2 CALLIPER Trial of Vidofludimus Calcium in Progressive Multiple Sclerosis Expected in the Secon... Full story

Yahoo Finance • 4 years ago

Companies Like Immunic (NASDAQ:IMUX) Could Be Quite Risky

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com made losses for many years after listing, if you had bought and held the shares since 1999, you would have made a fortune... Full story